Last update 25 Feb 2026
Hygieia Pharmaceuticals Co., Ltd.

Hygieia Pharmaceuticals Co., Ltd.

Private Company | Subsidiary Company|2021|Zhejiang Sheng, China|
www.hygieiapharma.com

Overview

Tags

Endocrinology and Metabolic Disease
Cardiovascular Diseases
Nervous System Diseases
siRNA

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease10
Nervous System Diseases2
Hemic and Lymphatic Diseases2
Infectious Diseases2
Neoplasms1
Top 5 Drug TypeCount
siRNA20
Oligonucleotide3
Small molecule drug2
miRNA1
Unknown1
Top 5 TargetCount
HBV RNA2
PCSK9(Proprotein convertase subtilisin kexin type 9)2
Lp(a)(lipoprotein(a))2
APOC3(Apolipoprotein C-III)2
THR-β(Thyroid hormone receptor beta)1

Related

27
Drugs associated with Hygieia Pharmaceuticals Co., Ltd.
Kylo-11
Target
Lp(a)
Mechanism
lipoprotein(a) inhibitors
Active Org.
Kylonova (Xiamen) Biopharma Co., Ltd.
Originator Org.
Kylonova (Xiamen) Biopharma Co., Ltd.
Active Indication
Atherosclerosis [+1]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
HT-101
Target
HBV RNA
Mechanism
HBV RNA inhibitors [+1]
Active Org.
Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd.Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. [+1]
Originator Org.
Hygieia Pharmaceuticals Co., Ltd.Hygieia Pharmaceuticals Co., Ltd.
Active Indication
Hepatitis B, Chronic [+2]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
Kylo-12
Target
APOC3
Mechanism
APOC3 inhibitors
Active Org.
Kylonova (Xiamen) Biopharma Co., Ltd.
Originator Org.
Kylonova (Xiamen) Biopharma Co., Ltd.
Active Indication
Hypertriglyceridemia
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
5
Clinical Trials associated with Hygieia Pharmaceuticals Co., Ltd.
NCT07327840
/ RecruitingPhase 2
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
NCT06783881
/ Active, not recruitingPhase 1
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects
NCT06363851
/ Active, not recruitingPhase 1
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-11 in Healthy Subjects
100 Clinical Results associated with Hygieia Pharmaceuticals Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Hygieia Pharmaceuticals Co., Ltd.
Login to view more data
100 Deals associated with Hygieia Pharmaceuticals Co., Ltd.
Login to view more data
100 Translational Medicine associated with Hygieia Pharmaceuticals Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
4
20
Preclinical
Phase 1
2
1
Phase 2
Other
5
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Kylo-11
 ( Lp(a) )		Lipoprotein (a) hyperlipoproteinemia
More
Phase 2
Kylo-0603
 ( THR-β )		Metabolic Dysfunction Associated Steatohepatitis
More
Phase 1
Kylo-12
 ( APOC3 )		Hypertriglyceridemia
More
Phase 1
HJY-40
Hemorrhage
More
Preclinical
HT-101
 ( HBV RNA )		Hepatitis B
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free